The IPO of Sudeep Pharma Ltd opened to strong enthusiasm, finishing its first day fully subscribed despite muted participation from institutional buyers. With a price band of ₹563–₹593, the offering quickly gained traction among retail investors and high-net-worth individuals, who drove the issue past the one-time mark even as qualified institutional buyers remained largely on the sidelines. This early imbalance between retail appetite and institutional caution has become a familiar pattern in mid-cap offerings, where large funds often wait for the final day before making substantial bids.
Adding to the upbeat sentiment was a firm grey-market premium, which hovered between ₹111 and ₹130 through the day. At this level, the stock’s potential listing range falls around ₹700–₹715 — roughly an 18–20 percent gain over the top end of the price band. Such estimates typically attract short-term traders seeking immediate listing gains, and Friday’s subscription trend reflected that momentum.
The positive tone also benefited from a strong anchor book. A day ahead of the IPO opening, Sudeep Pharma secured around ₹268 crore from institutional anchor investors, offering an early vote of confidence. The company, a key supplier of specialty excipients and mineral-based ingredients to pharmaceutical and nutraceutical manufacturers, has posted consistent growth and maintains stable profitability. Its niche positioning within the sector has bolstered investor interest, especially among retail participants.
Still, analysts have urged caution. Nearly ₹800 crore of the issue is an offer-for-sale, meaning proceeds will largely go to existing shareholders rather than being deployed for business expansion. Some market experts also consider the valuation at the upper end of the price band to be on the expensive side. The tepid response from QIBs on Day 1 further underscores that long-term conviction will only become clear as the issue nears closure.
With the IPO open until November 25, the next two days will reveal whether institutional investors join in with stronger commitments or maintain a wait-and-watch approach. For now, the offering’s early success and high GMP are likely to keep short-term sentiment buoyant, even as long-term investors track institutional demand more closely before making their final decision.
